MRTNZ

MRTNZ Investment Office · S&P 500 · The 360 Vantage

RVTY · NYSE

Revvity, Inc.

Industrials · Biotechnology: Laboratory Analytical Instruments

Reference price$111.51As of Jul 28, 2026
Market capitalization$12.44B
52-week range$81.22–$118.30
S&P 500 portfolio weight0.02%
Data qualitycomplete

Street view

Analyst targets

Published sell-side aggregation—not an MRTNZ forecast.

Low$90.00-19.3% vs. reference
Average$110.25-1.1% vs. reference
High$130.00+16.6% vs. reference
4 Buy7 Hold0 Sell

Forward calendar

Current earnings expectations

Consensus may change until the company reports.

Expected reportAug 4, 2026Jun 2026
Consensus EPS$1.233 estimates
Expected range$1.23–$1.23Low to high EPS
Dec 2026$5.25Street EPS consensus
Dec 2027$5.78Street EPS consensus
Dec 2028$6.43Street EPS consensus

Reported results

Annual financial snapshot

Fiscal period ended Dec 28, 2025.

MetricCurrentPrior
Revenue+3.7% YoY$2.86B$2.76B
Operating income$0.36B$0.35B
Net income$0.24B$0.27B
Operating cash flow$0.58B$0.63B
Capital expenditures($0.07B)($0.09B)

Current context

Related news

Company-linked articles surfaced by Nasdaq.

Zacks

Revvity (RVTY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Zacks

Revvity Develops High-Throughput T-SPOT.TB Platform for Clinical Labs

Zacks

Revvity to Launch Signals for Startups for Emerging Biotech Companies

Evidence

Sources & method

Nasdaq quote →Nasdaq summary →Earnings forecast →Annual financials →Official S&P 500-tracking holdings →

Facts, estimates, and scenarios are kept separate. Analyst targets and EPS expectations are third-party estimates, not MRTNZ forecasts. Index weight uses the official IVV portfolio as the denominator. Illustrative research, not investment advice.